Want to see ELUT full AI Analyst Report?
Top Page
Elutia
(NASDAQ:ELUT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$0.91
▼(-1.52% Downside)
Action:Reiterated
Date:08/22/26
ELUT scores in the low-50s primarily due to weak financial performance driven by severe, persistent cash burn and contracting revenue, despite improving margins and balance-sheet repair. Positives from the earnings call (funding/runway and product/regulatory progress) provide support, but are tempered by execution and regulatory timing risk. Technicals are neutral-to-soft and valuation appears optically cheap, but is less decisive given operating losses and cash-flow quality concerns.
Positive Factors
Improved Funding and Runway
The strengthened funding position gives Elutia more time to complete regulatory work and prepare NXT-41x for launch without relying immediately on equity markets. This supports continuity of operations and reduces near-term financing pressure.
Negative Factors
Persistent Cash Burn
Elutia remains dependent on external funding because its operations are not self-funding. Continued cash burn could require additional debt or equity, creating dilution and balance-sheet risk unless revenue growth and operating efficiency improve materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Funding and Runway
The strengthened funding position gives Elutia more time to complete regulatory work and prepare NXT-41x for launch without relying immediately on equity markets. This supports continuity of operations and reduces near-term financing pressure.
Read all positive factors
Elutia (ELUT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.30M
Dividend YieldN/A
Average Volume (3M)364.18K
Price to Earnings (P/E)0.7
Beta (1Y)-0.16
Revenue Growth-48.76%
EPS Growth-3.02%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.30
Shares Outstanding44,289,230
10 Day Avg. Volume362,745
30 Day Avg. Volume364,181
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.04
Price to Sales (P/S)2.33
P/FCF Ratio-0.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside443.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.6
Revenue Forecast (FY)$12.00M
Elutia Business Overview & Revenue Model
Company Description
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead developme...
How the Company Makes Money
Elutia makes money primarily by selling its drug-eluting biomaterial products to healthcare providers (e.g., hospitals and surgical centers) and/or through distributors, generating revenue when these products are purchased for use in surgical proc...
Elutia Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call conveyed strong strategic progress: the company secured substantial non‑equity funding, validated surgeon demand with an independent blinded survey, advanced manufacturing and regulatory preparations, and materially improved gross margins and cash runway. Counterbalancing this are short‑term revenue declines, a production disruption affecting SimpliDerm sales, increased R&D spending that widened adjusted EBITDA losses, and reliance on contingent transaction and clearance milestones. Overall, the positive operational, regulatory and funding developments outweigh the current commercial and execution risks.Positive Updates
Additional Non‑Equity Funding Secured
Up to $26 million of additional capital secured without an equity offering, including a $15 million Avenue Capital credit facility ($10M received, $5M contingent on NXT-41x clearance) and a SimpliDerm sale for up to $11M (including $8M cash at closing and $3M in milestones).
Negative Updates
Quarterly Revenue Decline
Total net sales for Q2 were $2.4M versus $2.7M a year ago, a decline of $0.3M or approximately -11.1% year‑over‑year; first half sales were $5.5M versus $5.7M (-3.5%).
Read all updates
Q2-2026 Updates
Positive
Negative
Additional Non‑Equity Funding Secured
Up to $26 million of additional capital secured without an equity offering, including a $15 million Avenue Capital credit facility ($10M received, $5M contingent on NXT-41x clearance) and a SimpliDerm sale for up to $11M (including $8M cash at closing and $3M in milestones).
Read all positive updates
Company Guidance
Management said Elutia is now “funded,” with up to $26.0M of additional capital (a $15.0M Avenue facility — $10.0M received, $5.0M available on NXT‑41x clearance — plus a SimpliDerm sale for up to $11.0M: $8.0M cash at closing and up to $3.0M in milestones, and an anticipated $8.0M escrow release in Q4), leaving $19.9M cash on hand at quarter‑end and $54.0M total current and projected cash sources to provide runway through at least 2028; key milestones are NXT‑41 clearance in Q4 2026, NXT‑41x clearance in H1 2027, a soft launch in H2 2027 and full commercial launch in 2028, with manufacturing qualified for scale (initial revenue capacity targeted at ≥$300M) and a long‑term gross‑margin target >80%. For context, Q2 net sales were $2.4M (H1 $5.5M), GAAP gross margin 59.6% (adjusted 70.7%), operating expenses $9.4M, loss from operations $8.0M, net loss $7.6M and adjusted EBITDA loss $4.6M; R&D rose $1.5M while litigation costs fell $1.9M. Commercial demand signals from a blinded survey of 50 board‑certified plastic/reconstructive surgeons (avg 11.6 years in practice, ~140 reconstructions/yr, 42% academic) showed a surgeon‑estimated infection rate of 17%, 86% saying current matrices increase infection risk, 96% rating rifampin+minocycline effective (64% “extremely effective”), 98% calling NXT‑41x new/different, 96% interested in using it in general practice, 100% would use it for high‑risk patients and 92% would champion it to their hospital VAC; management also cited published rates of 15–20% postoperative SSI, ~1 in 3 serious complications, up to 21% implant loss and average infected reconstruction cost >$48,000.Elutia Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.13M | 12.29M | 24.38M | 24.75M | 23.85M | 47.39M |
| Gross Profit | 7.02M | 6.60M | 10.71M | 11.05M | 11.64M | 19.02M |
| EBITDA | -24.13M | -13.46M | -45.89M | -31.92M | -27.30M | -15.72M |
| Net Income | 51.81M | 53.38M | -53.95M | -37.66M | -32.90M | -24.83M |
Balance Sheet | ||||||
| Total Assets | 43.65M | 62.35M | 36.13M | 43.43M | 68.84M | 67.17M |
| Cash, Cash Equivalents and Short-Term Investments | 19.90M | 36.35M | 13.24M | 19.28M | 16.99M | 30.39M |
| Total Debt | 4.38M | 11.17M | 24.01M | 23.95M | 25.45M | 23.24M |
| Total Liabilities | 27.90M | 34.68M | 82.39M | 82.03M | 73.87M | 53.65M |
| Stockholders Equity | 15.75M | 27.67M | -46.26M | -38.60M | -5.03M | 13.52M |
Cash Flow | ||||||
| Free Cash Flow | -45.48M | -46.69M | -23.31M | -22.11M | -21.97M | -15.81M |
| Operating Cash Flow | -43.99M | -44.81M | -22.66M | -21.76M | -21.43M | -15.45M |
| Investing Cash Flow | 78.83M | 78.56M | -474.00K | 14.21M | -540.00K | -369.00K |
| Financing Cash Flow | -23.44M | -10.64M | 17.09M | 9.84M | 8.54M | 6.71M |
Elutia Technical Analysis
Positive
0.92
Price Trends
0.93
Positive
1.01
Positive
0.94
Positive
Market Momentum
<0.01
Negative
61.60
Neutral
84.90
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELUT, the sentiment is Positive. The current price of 0.92 is above the 20-day moving average (MA) of 0.89, below the 50-day MA of 0.93, and below the 200-day MA of 0.94, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.60 is Neutral, neither overbought nor oversold. The STOCH value of 84.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELUT.
Elutia Risk Analysis
Elutia disclosed 66 risk factors in its most recent earnings report. Elutia reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elutia Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $95.13M | -3.37 | -311.07% | ― | ― | 61.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $42.30M | 0.73 | 940.81% | ― | -48.76% | -3.02% | |
49 Neutral | $157.53M | -1.11 | -49.02% | ― | ― | 34.92% | |
49 Neutral | $122.53M | -3.27 | -129.93% | ― | 306.42% | 70.84% | |
47 Neutral | $31.08M | -3.70 | -113.58% | ― | ― | ― |
* Healthcare Sector Average
ELUT
Elutia
1.01
-1.39
-57.92%
IGC
IGC Pharma
0.30
-0.09
-22.05%
PYPD
PolyPid
5.10
1.68
49.12%
OKUR
OnKure Therapeutics
3.85
1.10
40.00%
RANI
Rani Therapeutics Holdings
0.89
0.30
51.02%
Elutia Corporate Events
Business Operations and StrategyM&A Transactions
Elutia Divests SimpliDerm to Refocus on NXT-41x
Positive
Aug 21, 2026
On August 17, 2026, Elutia completed the sale of its SimpliDerm human acellular dermal matrix breast reconstruction business to Cellution Biologics for up to $11 million in cash consideration. The deal includes $8 million received at closing, subj...
Delistings and Listing ChangesRegulatory Filings and Compliance
Elutia Receives Nasdaq Notice on Listing Compliance Risk
Negative
Aug 7, 2026
On August 6, 2026, Elutia Inc. disclosed it had received a Nasdaq notice that its Class A common stock had closed below the $1.00 per share minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq Capital Market...
Business Operations and StrategyM&A Transactions
Elutia Divests SimpliDerm Assets to Refocus Strategy
Positive
Jul 20, 2026
On July 16, 2026, Elutia Inc. signed an asset purchase agreement to sell substantially all assets of its SimpliDerm human acellular dermal matrix business for breast reconstruction to Cellution Biologics Inc. for up to $11 million, including $8 mi...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Elutia Shareholders Approve Amended Incentive Plan and Governance
Positive
Jun 16, 2026
Elutia’s board approved a first amendment to its 2020 Incentive Award Plan on April 22, 2026, which was subsequently approved by stockholders at the June 11, 2026 annual meeting. The amendment increases the shares available for equity awards...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.